The effects of inhaled nitric oxide on cardiac pathology and energy metabolism in a canine model of smoke inhalation injury.
OBJECTIVE
The effects of inhaled nitric oxide (NO) on cardiac pathology and energy metabolism were studied in a canine model of smoke inhalation injury.


METHODS
Twenty-one dogs were randomly divided into three groups: four dogs constituted the normal control group (group N), eight dogs subjected to smoke inhalation followed by O(2) inhalation (FiO(2)=0.45) constituted the injury control group (group C), and nine dogs inhaling a mixture of O(2) and 45ppm nitric oxide after smoke exposure served as the treatment group (group T). Myocardial zymograms were continuously measured, and ventricular muscles were examined for histopathology in the end of the experiment.


RESULTS
Lactate dehydrogenase (LDH), alpha-hydroxybutyrate dehydrogenase (alpha-HBD), creatine kinase (CK) and glutamic oxalacetic transaminase (GOT) in group T were less than those in group C(P<0.05, or P<0.01). ATP content and energy charge (EC) in group T were higher significantly than those in group C(P<0.01). Light microscopy and electron microscopy indicated that the ventricular pathologic changes in group T were milder than in control group.


CONCLUSIONS
Nitric oxide inhalation relieved myocardial damage and improved energy metabolism.
Qi
Shunzhen
S
The center of Burn and Plastic of HeBei Province, Bethune International Peace Hospital, Hebei Province 050082, Shijiazhuang City, PR China. sunrise528@sohu.com
Sun
Weihai
W
D008841:Actin Cytoskeleton / Q000648:ultrastructure; D000280:Administration, Inhalation; D000818:Animals; D015415:Biomarkers / Q000097:blood; D004195:Disease Models, Animal; D004285:Dogs; D045462:Endothelium-Dependent Relaxing Factors / Q000627:therapeutic use*; D004734:Energy Metabolism / Q000187:drug effects*; D004798:Enzymes / Q000097:blood; D006335:Heart Injuries / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D006352:Heart Ventricles / Q000648:ultrastructure; D009206:Myocardium / Q000648:ultrastructure; D009569:Nitric Oxide / Q000627:therapeutic use*; D015208:Smoke Inhalation Injury / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology
D015415:Biomarkers; D045462:Endothelium-Dependent Relaxing Factors; D004798:Enzymes; D009569:Nitric Oxide